Introduction {#s001}
============

Lymphedema is an incurable, debilitating, and progressive condition, characterized by persistent swelling of one or more parts of the body, because of the impairments in lymph transport. This chronic and progressive disease can occur at any time after cancer surgeries, can arise from congenital malformation of the lymphatic system, or because by damage to lymphatic vessels.^[@B1],[@B2]^ It is a major health care problem in both developed and nondeveloped countries. It is serious because of its long-term physical and psychosocial consequences for the patients, if left untreated. When lymphedema is not diagnosed and treated in the earlier stages, the prognosis for these patients is worse and treatments are more costly. Lymphedema frequently leads to physical, emotional, and psychological challenges and impairs the quality of life (QoL) if it is underrecognized and undertreated.^[@B3],[@B4]^ Treatment cost of lymphedema has also been identified as a barrier. The support and funding of medical conditions and complex care needs will ease the stress and treatment burden associated with lymphedema.^[@B5]^ There are also challenges of managing complex lymphedema patients with obesity, and those associated with chronic medical conditions and wounds.^[@B6]^ Therefore the awareness of this chronic condition by both health professionals and patients---knowledge comprising the characteristics of lymphedema patients, difficulties finding appropriate treatments or funding for care, and the impact of disease on functional, psychosocial status, and QoL are of great importance, especially in developing countries.

Lymphedema has been a rising condition in Turkey over the past 10--12 years. Awareness about lymphedema was low and the treatment methods were unknown and certified lymphedema specialists were lacking until recent years.^[@B7]^ There are no data about the incidence of lymphedema in Turkey. Patient characteristics or experiences of some patients are reported in some small studies.^[@B7]^

The LIMPRINT^©^ study is an international multisite health service-based study to determine the prevalence and functional impact of lymphedema/chronic edema in the adult population of member countries of the International Lymphoedema Framework (ILF). It aims to estimate the proportion of patients with chronic edema and those with a concurrent wound.

Turkey has been a member of the ILF since 2017 under the auspices of the Anatolian/Turkish Lymphedema Association (ALA), but the LIMPRINT study was first noticed by Dr. Borman, Chair of the ALA at the ILF Meeting in Glasgow, 2014 ([www.ilfconference.org](www.ilfconference.org)). She was influenced by the presentations from other countries and was interested to find out how a study of Turkish lymphedema patients could be made and compare it with different countries. The participation in LIMPRINT study would be valuable and provide important information about the demographic, social, and QoL characteristics of Turkish patients. The study results would show the current status and characteristics of lymphedema patients, treatment conditions, the unmet need for diagnosis and treatment of those suffering with the condition, and burden of the disease in both patients and families in Turkey. The LIMPRINT study would also allow the comparison with different populations from different countries. In addition the data would be informative for developing national health polices and reimbursement procedures in diagnosis and treatment of lymphedema in Turkey.

Materials and Methods {#s002}
=====================

Considering all these points, an interest in being part of LIMPRINT was shared with the executive members of ALA, and after unanimous approval, a request for Turkey to be involved was officially made in 2014 and accepted by the ILF.

Two main institutions are related to lymphedema in Turkey: Anatolian Lymphedema Association and Hacettepe University Lymphedema Practice and Research Center. Therefore the participation in this international multicenter study proposal was sent to the health professional delegates of the ALA from different parts of Turkey working in centers who are managing patients with lymphedema. In addition, Hacettepe University Lymphedema Practice and Research Center actively engaged and recruited a great number of patients in collaboration with the Department of Physical Medicine and Rehabilitation. Vascular surgeons and nurses were also informed. Most of the surgeons were not interested in joining the study. After this initial information the proposal was sent to 10 centers with 8 accepting to be part of the study.

The local steering groups were Anatolian (Turkish) Lymphedema Association and Hacettepe University Lymphedema Practice and Research Center. The stakeholders were as follows, from five different areas of the country: (1)University of Hacettepe Faculty of Medicine Department of Physical Medicine and Rehabilitation (PMR) and Hacettepe University Lymphedema Research and Practice Center (Dr. Pınar Borman, Dr. Merve Denizli, Dr. Ayşegül Yaman, Dr. Oya Özdemir, Dr. Fusun Terzioğlu, and Ayşe Arikan Dönmez).(2)Ankara Rehabilitation Training and Research Hospital (Dr. Meltem Vural, Dr. Sibel Ünsal Delialioğlu).(3)Ankara Training and Research Hospital Clinic of PMR (Dr. Figen Ayhan, Dr. Burcu Duyur Çakıt, Dr. Seçil Vural).(4)Kirsehir Ahi Evran University Department of PMR (Dr. Eda Kurt).(5)Ege University Medical Faculty Department of PMR, İzmir (Dr. Sibel Eyigör).(6)Istanbul Rehabilitation Training and Research Hospital Clinic of PMR (Dr. Evrim Coşkun Çelik).(7)Istanbul Kanuni Sultan Süleyman Education and Research Hospital (Dr. Muge Kepekçi).(8)Manisa Celal Bayar University Medical Faculty Department of PMR (Lale Cerrahoğlu).

All centers gained approval from their local ethical committees. The coordinator of the Turkish study was the chair of ALA and director of the HU Lymphedema Practice and Research Center---P.B. All the LIMPRINT questionnaires were translated to Turkish and back translated to ensure accuracy of language. The QoL questionnaires lymphedema quality of life (LYMQOL)-arm and LYMQOL-leg^[@B10]^ did not have Turkish validation. The cross-cultural Turkish validation studies of the LYMQOL-arm and LYMQOL-leg questionnaires were performed before this study began adding further validity to the methods.^[@B11],[@B12]^ Then the Turkish data collection forms were sent to the included centers. All the centers filled the questionnaires and sent them by ordinary mail to the coordinator and they were then returned when completed in batches of 30. Data entry was undertaken from one center (Hacettepe University) with each center given an individual code.

The patients were recruited to the study according to the inclusion and exclusion criteria of the LIMPRINT study protocol. Data were collected using a Core Tool to determine the prevalence of chronic edema and a set of five Module Tools to assess the impact of chronic edema on the lives of sufferers. Data were entered into a secure central on-line database. The core tools included questions about type of facility in which data are collected, demographics, level of obesity, mobility, relevant comorbidities, classification and history of lymphedema, cellulitis history, categories of treatment, site of swelling, wound area, access to treatment, and subjective control of swelling. The module tools comprised demographics and disability, QoL, details of swelling, wounds, and cancer. The Turkish version of World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) was used to assess disability,^[@B13],[@B14]^ and LYMQOL^[@B10]^ and European Quality of Life Five Dimensional Questionnaire (EQ-5D)^[@B15],[@B16]^ tools were used to assess QoL.

WHODAS 2.0 is a validated 12-item disability assessment schedule. It includes questions exploring the patient\'s personal circumstances for example, housing, employment, and education.^[@B14],[@B15]^

LYMQOL is a validated condition-specific QoL assessment instrument (it is not validated for patients with lymphatic filariasis) that assesses the impact of lymphedema on the patient\'s everyday living and health-related QoL. There is a tool for patients with lymphedema of the upper limb and one for the lower limb.^[@B11]^

EQ-5D is a generic QoL instrument applicable to a wide range of health conditions and provides a simple descriptive profile and single index value for health status.^[@B15]^ EQ-5D is primarily intended for self-completion and is simple and quick to complete. Turkish validation has previously been made and used in this study.^[@B16]^

Results {#s003}
=======

A total of 1051 patients from eight centers of five different geographical areas took part in the study. Most of the patients were recruited from specialist lymphedema services. The majority of patients were women, housewives, nonobese, had full range of movement, and walked independently. The most common comorbidity was diabetes followed by hypertension. Half the patients stated that their edema was not under control. The core demographic properties of the patients are given in [Table 1](#T1){ref-type="table"}.

###### 

The Core Data of Turkish Patients Comprising the Demographic and Disease-Related Variables (*N* = 051)

                                          n *(%)*
  --------------------------------------- ---------------
  Type of facility                        
   Acute inpatient                        53 (5.04)
   Acute outpatient                       426 (40.53)
   General practitioner                   1 (0.10)
   Nursing home                           2 (0.19)
   Specialist Lymphoedema Centre          569 (54.14)
  Gender                                  
   Female                                 980 (93.24)
   Male                                   71 (6.76)
  Age                                     
   Mean (minimum, maximum)                53.42 (7--85)
   Median                                 54
  Age groups, years                       
   5--14                                  5 (0.48)
   15--44                                 231 (21.98)
   45--64                                 615 (58.52)
   65--74                                 161 (15.32)
   75--84                                 38 (3.62)
   85 plus                                1 (0.10)
  Obesity                                 
   Under weight                           14 (1.33)
   Normal weight                          630 (59.94)
   Obese                                  357 (33.97)
   Morbidly obese                         50 (4.76)
  Lower limb mobility                     
   Bed bound                              10 (0.95)
   Chair bound                            13 (1.24)
   Walks with aid                         71 (6.76)
   Walks unaided                          957 (91.06)
  Upper limb mobility                     
   No function                            3 (0.29)
   Limited range of movement              138 (13.13)
   Full range of movement                 910 (86.58)
  Comorbidity                             
   Diabetes mellitus                      210 (19.98)
   Heart failure/ischemic heart disease   84 (7.99)
   Neurological disease                   33 (3.14)
   Peripheral arterial disease            115 (10.94)
   None of these                          711 (67.65)
  Subjective control of swelling          
   Yes                                    393 (48.70)
   No                                     414 (51.30)

The classification of lymphedema was mostly secondary (85%) and caused by cancer (79%) with 85% suffering from breast cancer, followed by venous insufficiency, lipedema, immobility, and obesity. The cellulitis and infection or hospitalization for cellulitis and infection were infrequent. The duration of lymphedema was \<5 years in majority of the patients. The whole group disease characteristics and distribution of variables according to gender are given in [Table 2](#T2){ref-type="table"}.

###### 

The Turkish Edema Characteristics in the Core Tool (*N* = 051)

                                   *Total (*N = *1051)*   *Female (*n = *980)*   *Male (*n = *71)*   *χ^2^ (df) or* p*-value*
  -------------------------------- ---------------------- ---------------------- ------------------- --------------------------------------
  Classification                                                                                     
   Primary                         152 (14.48)            129 (13.18)            23 (32.39)          19.75 (1)
   Secondary                       898 (85.52)            850 (86.82)            48 (67.61)          \<0.001
  Secondary swelling                                                                                 
   Cancer                          717 (79.58)            698 (81.92)            19 (38.78)          53.09 (1)
   Noncancer                       184 (20.42)            154 (18.08)            30 (61.22)          \<0.001
  Cancer-related secondary LE                                                                        
   Treatment related               715 (99.72)            696 (99.71)            19 (100.0)          0.99^[a](#tf1){ref-type="table-fn"}^
   Metastatic                      8 (1.12)               7 (1.00)               1 (5.26)            0.19^[a](#tf1){ref-type="table-fn"}^
  Noncancer-related secondary LE                                                                     
   Venous                          92 (50.0)              71 (46.10)             21 (70.00)          0.017
   Immobility                      48 (26.09)             36 (23.38)             12 (40.00)          0.058
   Obesity                         84 (45.65)             74 (48.05)             10 (33.33)          0.14
   Lymphatic filariasis            5 (2.72)               4 (2.6)                1 (33.3)            0.99^[a](#tf1){ref-type="table-fn"}^
   Noncancer other                 57 (30.98)             51 (33.12)             6 (20.00)           0.16
  Duration                                                                                           
   \<6 Months                      273 (26.00)            260 (26.56)            13 (18.31)           
   6 Months to 1 year              128 (12.19)            122 (12.46)            6 (8.45)             
   1--2 Years                      142 (13.52)            133 (13.59)            9 (12.68)           6.64 (5)
   2--5 Years                      219 (20.86)            201 (20.53)            18 (25.35)          0.25
   5--10 Years                     146 (13.90)            136 (13.89)            10 (14.08)           
   10+ Years                       142 (13.52)            127 (12.97)            15 (21.13)           
  History of cellulitis                                                                              
   Yes                             232 (22.07)            206 (21.02)            26 (36.62)          9.37 (1)
   No                              819 (77.93)            774 (78.98)            45 (63.38)          0.002
  Infection in last year                                                                             
   Yes                             171 (73.71)            149 (72.33)            22 (84.62)          1.80 (1)
   No                              61 (26.29)             57 (27.67)             4 (15.38)           0.18
  Lower limb swelling                                                                                
   Yes                             426 (40.57)            367 (37.49)            59 (83.10)          57.12 (1)
   No                              624 (59.43)            612 (62.51)            12 (16.90)          \<0.001
  Upper limb swelling                                                                                
   Yes                             628 (59.81)            615 (62.82)            13 (18.31)          54.56 (1)
   No                              422 (40.19)            364 (37.18)            58 (81.69)          \<0.001

Fisher\'s exact test.

LE, lymphedema.

The treatment categories of the patients are given in [Table 3](#T3){ref-type="table"}. The majority of patients did not get any treatment or advice before (66.4%). The most common treatment was exercise (50%), skin care advice (47%), massage (43%), and compression garment (40%). Psychological support was neglected in 91% of patients. A great number of patients expressed that their swelling was not under control. In Turkey the complex decongestive therapy is free in government hospitals for patients with obligative health insurance. Therefore the majority of the attendants replied to this question that treatment was free. But the cost of bandages for multilayer short stretch bandaging are not reimbursed and the amount of compression garments are only partially reimbursed in Turkey. Nearly 40% of the patients stated that if the treatment was not free, they could not cover the expenses for the treatment. Most of the patients suggested that lymphedema treatment was available for free within a reasonable travelling distance, as they are living in big cities or metropoles, but more than one third of them declared that the distance would prevent patients from accessing specialized centers. As the majority of patients did not have wounds or complicated lymphedema, they were not related to discharge from hospital or long stays in care centers ([Table 4](#T4){ref-type="table"}).

###### 

The Treatment Categories (*N* = 051)

                                             *All patient (*N* = 1051),* n *(%)*   *Female (*n* = 980),* n *(%)*   *Male (*n* = 71),* n *(%)*   *χ^2^ (df) or* p*-value*
  ------------------------------------------ ------------------------------------- ------------------------------- ---------------------------- --------------------------------------
  No treatment offered                                                                                                                          
   No                                        698 (66.41)                           652 (66.53)                     46 (64.79)                   0.09 (1)
   Yes                                       353 (33.59)                           328 (33.47)                     12 (35.21)                   0.76
  Skin care advice                                                                                                                              
   No                                        552 (52.52)                           516 52.65)                      36 (50.70)                   0.10 (1)
   Yes                                       499 (47.48)                           464 (47.35)                     35 (49.30)                   0.75
  Wound dressing                                                                                                                                
   No                                        1020 (97.05)                          957 (97.65)                     63 (88.73)                   18.40 (1)
   Yes                                       31 (2.95)                             23 (2.35)                       8 (11.27)                    \<0.001
  Antibiotic                                                                                                                                    
   No                                        934 (88.87)                           880 (89.80)                     54 (76.06)                   12.63 (1)
   Yes                                       117 (11.13)                           100 (10.20)                     17 (23.94)                   \<0.001
  Massage                                                                                                                                       
   No                                        594 (56.52)                           553 (56.43)                     41 (57.57)                   0.04 (1)
   Yes                                       457 (43.48)                           427 (43.57)                     30 (42.25)                   0.83
  Physiotherapy                                                                                                                                 
   No                                        963 (91.63)                           902 (92.04)                     61 (85.92)                   3.24 (1)
   Yes                                       88 (8.37)                             78 (7.96)                       10 (14.08)                   0.07
  Compression garment                                                                                                                           
   No                                        638 (60.70)                           599 (61.12)                     39 (54.93)                   1.06 (1)
   Yes                                       413 (39.30)                           381 (38.88)                     32 (45.07)                   0.30
  Multilayer bandage                                                                                                                            
   No                                        716 (68.13)                           669 (68.27)                     47 (66.20)                   0.13 (1)
   Yes                                       335 (31.87)                           311 (31.73)                     24 (33.80)                   0.72
  Pneumatic compression pumps                                                                                                                   
   No                                        903 (85.92)                           846 (86.33)                     57 (80.28)                   2.00 (1)
   Yes                                       148 (14.08)                           134 (13.67)                     14 (19.72)                   0.16
  Debulking---lipedema---lymphatic surgery                                                                                                      
   No                                        1042 (99.14)                          971 (99.08)                     71 (100.00)                   
   Yes                                       9 (0.86)                              9 (0.92)                        0 (0)                        0.99^[a](#tf3){ref-type="table-fn"}^
  Exercise advice                                                                                                                               
   No                                        517 (49.19)                           479 (48.88)                     38 (53.52)                   0.57 (1)
   Yes                                       534 (50.81)                           501 (51.12)                     33 (46.48)                   0.45
  Cellulitis advice                                                                                                                             
   No                                        811 (77.16)                           761 (77.65)                     50 (70.42)                   1.96 (1)
   Yes                                       240 (22.84)                           219 (22.35)                     21 (29.58)                   0.16
  Psychological support                                                                                                                         
   No                                        963 (91.63)                           900 (91.84)                     63 (88.73)                   0.83 (1)
   Yes                                       88 (8.37)                             80 (8.16)                       8 (11.27)                    0.36
  Complex decongestive therapy                                                                                                                  
   No                                        1035 (98.48)                          965 (98.47)                     70 (98.59)                   0.99^[a](#tf3){ref-type="table-fn"}^
   Yes                                       16 (1.52)                             15 (1.53)                       1 (1.41)                      
  Control of swelling                                                                                                                           
   No                                        414 (51.30)                           372 (49.80)                     42 (70.00)                   9.07 (1)
   Yes                                       393 (48.70)                           375 (50.20)                     18 (30.00)                   0.003

Fisher\'s exact test.

###### 

The Questions Related to Access, Distance, and Patient Costs of Treatment (*n* = 009)

                                                                                                   *Total (%)*   *Female (%)*   *Male (%)*   *χ^2^ (df) or* p*-value*
  ------------------------------------------------------------------------------------------------ ------------- -------------- ------------ --------------------------
  \(1\) Are patients\' entire treatment complex decongestive therapy free?                                                                   
   Yes                                                                                             779 (77.21)   730 (77.49)    49 (73.13)   0.68 (1)
   No                                                                                              230 (22.79)   212 (22.51)    18 (26.87)   0.41
  \(2\) If it is not free, could the patient cover the treatment expenses?                                                                   
   Yes                                                                                             538 (61.14)   504 (61.61)    34 (54.84)   1.11 (1)
   No                                                                                              342 (38.86)   314 (38.39)    28 (45.16)   0.29
  \(3\) Is lymphedema treatment available in a reasonable distance?                                                                          
   Yes                                                                                             785 (77.95)   753 (80.02)    32 (48.48)   35.69 (1)
   No                                                                                              222 (22.05)   188 (19.98)    34 (51.52)   \<0.001
  \(4\) Does the distance prevent the patient from accessing a specialist center?                                                            
   Yes                                                                                             302 (36.39)   276 (35.84)    26 (43.33)   1.35 (1)
   No                                                                                              528 (63.61)   494 (64.16)    34 (56.67)   0.25
  \(5\) Do patients\' lymphedema/wounds prevent discharge from hospital?                                                                     
   Yes                                                                                             47 (10.26)    35 (8.47)      12 (26.67)   14.58 (1)
   No                                                                                              411 (89.74)   378 (91.53)    33 (73.33)   \<0.001
  \(6\) Is the patient\'s lymphedema/wound the main reason for remaining in long-term care?                                                  
   Yes                                                                                             79 (17.59)    63 (15.40)     16 (40.00)   15.20 (1)
   No                                                                                              370 (82.41)   346 (84.60)    24 (60.00)   \<0.001
  \(7\) Is the patient\'s lymphedema/wound the main reason for remaining in long-term home care?                                             
   Yes                                                                                             50 (11.47)    40 (10.05)     10 (26.32)   9.04 (1)
   No                                                                                              386 (88.53)   358 (89.95)    28 (73.68)   0.003

According to the demographics in the module data, most patients were in the age range of 45--64 years and were living with their partners or relatives. Eighty percent of the patients were owner occupiers and 55% had their own vehicle. As most of the patients were housewives, they were not the main provider for their family. Fifty-two percent of the attendants had primary school education with only 20% having a university diploma. As most patients were housewives (55%), they (92%) did not have to change or stop their job/work that would affect their family income ([Table 5](#T5){ref-type="table"}).

###### 

Demographic Characteristics (*n* = 048)

                                                                                       n *(%)*
  ------------------------------------------------------------------------------------ ------------------------
  Living with                                                                          
   No one/live alone                                                                   109 (10.4)
   Partner/spouse                                                                      724 (69.1)
   Other relative                                                                      212 (20.2)
   Friend                                                                              2 (0.2)
   Other                                                                               1 (0.1)
  Living accommodation                                                                 
   Owner occupier                                                                      838 (80)
   Public rented                                                                       11 (1.1)
   Privately rented                                                                    189 (18)
   Nursing home                                                                        5 (0.5)
   Hospital                                                                            1 (0.1)
   Supported living accommodation                                                      4 (0.4)
  Patients who had a car or other vehicle                                              
   Yes                                                                                 582 (55.5)
   No                                                                                  466 (44.5)
  Working/job                                                                          
   Employed full time                                                                  148 (14.1)
   Employed part time                                                                  25 (2.4)
   Retired                                                                             208 (19.8)
   Unemployed looking for work                                                         20 (1.9)
   Not working because of illness                                                      68 (6.5)
   Looking after the house (housewives)                                                581 (55.4)
   Full or part-time education or training                                             15 (1.4)
   Other                                                                               3 (0.3)
  Patients were the main provider                                                      
   Yes                                                                                 202 (19.3)
   No                                                                                  846 (80.7)
  Age of graduation, mean ± SD, median (minimum to maximum)                            16.3 ± 4.9, 17 (8--45)
  Degree of graduation                                                                 
   None (elementary school)                                                            549 (52.4)
   School certificate/diploma                                                          265 (25.3)
   University diploma/degree                                                           215 (20.5)
   Master\'s degree                                                                    9 (0.9)
   Doctorate                                                                           10 (1)
  Patients who had to change their job or education/training                           
   Yes                                                                                 52 (5)
   No                                                                                  996 (95)
  Patients who had to stop work or education/training                                  
   Yes                                                                                 82 (7.8)
   No                                                                                  966 (92.2)
  Patients who had been affected/reduced their family income because of the swelling   
   Yes                                                                                 99 (9.5)
   No                                                                                  949 (90.6)

SD, standard deviation.

The details of swelling in the module data are given in [Table 6](#T6){ref-type="table"}. The site of swelling was the upper extremity (arms) in 59% followed by legs (39.8%), Overall 55% did not have pitting edema. Tissues in the swollen area were mostly soft with 41% having a significant shape distortion. Thirty-six percent of the patients had not been told the reason for the swelling. Stemmer sign was positive in 75% of patients with lower extremity and 49% of patients in upper extremity swelling. The majority had ISL grade 2 swelling (61.7%) and 27.5% had ISL grade 1 lymphedema. The disability and QoL scores are given in [Table 7](#T7){ref-type="table"}. Most of the patients had impaired QoL and decreased functionality. These were prominent especially in lower limb chronic edema patients.

###### 

Details of Swelling (*n* = 050)

                                                           n *(%)*
  -------------------------------------------------------- ------------
  Pitting                                                   
   Yes                                                     475 (45.2)
   No                                                      575 (54.8)
  Tissue in swollen area                                    
   Soft                                                    715 (68.1)
   Hard                                                    335 (31.9)
  Shape distortion in the affected limb                     
   Yes                                                     436 (41.5)
   No                                                      614 (58.5)
  Patients who had been told the reason for the swelling    
   Yes                                                     671 (63.9)
   No                                                      379 (36.1)
  The site of swelling                                      
   Arm                                                     617 (59.0)
   Leg                                                     416 (39.8)
   Both                                                    12 (1.2)
  Stemmers sign                                             
   Hand---positive                                         313 (49.3)
   Foot---positive                                         329 (75.8)
  Severity of the swelling                                  
   ISL stage I                                             289 (27.5)
   ISL stage II                                            648 (61.7)
   ISL stage III                                           113 (10.8)

ISL, International Society of Lymphology.

###### 

The Disability and Quality-Of-Life Scores (*n* = 050)

                                         *Mean* ± *SD*   *Median*   *Minimum to maximum*
  -------------------------------------- --------------- ---------- ----------------------
  WHODAS overall scores *N* = 1050       31.7 ± 21.8     27.1       0--100
  EQ-5D scores (*n* = 1050)              0.56 ± 0.32     0.62       0.59--1
  Overall health scores (*n* = 1050)     61.2 ± 20.5     60         0--100
  LYMQOL---upper extremity (*n* = 630)                               
   Function                              17.5 ± 6.1      16         10--40
   Appearance                            9.4 ± 3.6       9          5--20
   Symptoms                              12.3 ± 4        12         6--24
   Emotion                               11.3 ± 4.2      11         6--24
   Overall                               6.6 ± 1.8       7          0--10
  LYMQOL---lower extremity (*n* = 429)                               
   Function                              19.1 ± 6.4      19         8--32
   Appearance                            17.5 ± 5.9      17         7--28
   Symptoms                              11.8 ± 3.9      11         5--20
   Emotion                               12.9 ± 4.5      12         6--24
   Overall                               5.1 ± 2.1       5          0--10

EQ-5D, European Quality of Life Five Dimensional Questionnaire; LYMQOL, lymphedema quality of life; WHODAS, World Health Organization Disability Assessment Schedule.

The cancer data showed the majority (84%) had breast cancer followed by endometrium (8%), cervix (2.8%), and ovarian (2.4%) cancers. All but five of them had received treatment for cancer, with 53% having local cancer and 32% being in remission. The most common type of cancer treatment was surgery followed by chemotherapy and radiation therapy. The duration of lymphedema was \<5 years in the majority of the patients (88.8%). Twenty-one percent of patients developed swelling within 3 months, 32% in 3--11 months, and 34% developed in 1--5 years after cancer treatment. The summary of cancer data is given in [Table 8](#T8){ref-type="table"}.

###### 

Details of Cancer (*n* = 15)

                                                                                                                                        N *(%)*
  ------------------------------------------------------------------------------------------------------------------------------------- ------------
  Patients who had treatment for cancer                                                                                                  
   Yes                                                                                                                                  710
   No                                                                                                                                   5
  Duration between swelling and cancer treatment (How long after the cancer treatment did you develop swelling in the affected area?)    
   \<3 Months                                                                                                                           152 (21.3)
   3--11 Months                                                                                                                         234 (32.7)
   1--5 Years                                                                                                                           249 (34.8)
   6--9 Years                                                                                                                           40 (5.6)
   10+ Years                                                                                                                            32 (4.5)
   Unknown                                                                                                                              5 (0.7)
   Not applicable                                                                                                                       3 (0.4)
  Current cancer status                                                                                                                  
   Cured/remission                                                                                                                      229 (32.0)
   Local cancer                                                                                                                         383 (53.6)
   Distant metastases                                                                                                                   56 (7.8)
   Do not know                                                                                                                          47 (6.6)
  Type of cancer                                                                                                                         
   Bladder cancer                                                                                                                       2 (0.3)
   Breast cancer                                                                                                                        603 (84.3)
   Cervical cancer                                                                                                                      20 (2.8)
   Colorectal cancer                                                                                                                    2 (0.3)
   Endometrial cancer                                                                                                                   57 (8.0)
   Head and neck cancer                                                                                                                 1 (0.1)
   Melanoma cancer                                                                                                                      6 (0.8)
   Ovarian cancer                                                                                                                       17 (2.4)
   Vulval cancer                                                                                                                        2 (0.3)
   Other cancer                                                                                                                         16 (2.2)
  Type of cancer treatments                                                                                                              
   Surgery                                                                                                                              703 (98.3)
   Radiation therapy                                                                                                                    569 (79.6)
   Chemotherapy                                                                                                                         595 (83.2)
   Hormone therapy                                                                                                                      306 (42.8)
   Molecular target therapy                                                                                                             16 (2.2)
   Other                                                                                                                                1 (0.1)

The majority of patients (98%) did not have a wound. Of the patients with wounds, 55% had one to two wounds mostly grade 2 small venous ulcers with low exudate located in the legs. Most patients looked after their own wounds followed by physicians and hospital nurses. Nearly half of the wounds did not have signs of infection (47%) and had been present \<6 months in the majority of the patients (70%). The wound details are given in [Table 9](#T9){ref-type="table"}.

###### 

Details of Wounds (*n* = 1)

                                           N *(%)*
  ---------------------------------------- -----------
  Provider wound care                       
   Physician                               13 (61.9)
   Podiatrist                              0
   Self-care                               14 (66.7)
   Family/friend                           6 (28.6)
   Hospital nurse                          11 (52.4)
   Practice nurse                          0
   Care home nurse                         2 (9.5)
   Wound care specialist nurse             0
   Home care/community nurse               1 (4.8)
   Lymphedema specialist nurse/therapist   1 (4.8)
   Other                                   0
  No. of wounds                             
   One                                     7 (33.3)
   Two                                     9 (42.9)
   Three                                   2 (9.5)
   Four                                    1 (4.8)
   Five                                    1 (4.8)
   Six                                     1 (4.8)
   Missing                                 1 (4.8)
  Pressure ulcer                            
   None                                    13
   Grade 1                                 0
   Grade 2                                 5 (62.5)
   Grade 3                                 2 (25.0)
   Grade 4                                 1 (12.5)
  Leg/foot ulcer cause                      
   No leg/foot ulcer                       6
   Venous ulcer                            6 (40.0)
   Arterial ulcer                          1 (6.7)
   Mixed (venous/arterial)                 1 (6.7)
   Neuropathic                             1 (6.7)
   Neuroischemic                           0
   Other foot ulcer                        2 (13.3)
   Do not know ulcer type                  7 (46.7)
  Acute/surgical wound                      
   No acute/surgical wound                 10
   Primary closure                         0
   Open surgical wound                     0
   Postsurgical breakdown                  2 (18.2)
   Dehisced wound                          5 (45.5)
   Traumatic wound                         2 (18.2)
   Do not know wound type                  2 (18.2)
  Exudate level                             
   None                                    9 (42.9)
   Low                                     7 (33.3)
   Medium                                  4 (19.1)
   High                                    1 (4.8)
  Location of the wounds                    
   Head or neck                            21 (100)
   Arms                                    21 (100)
   Chest                                   19 (90.5)
   Abdomen                                 21 (100)
   Back                                    20 (95.2)
   Sacrum                                  21 (100)
   Hips                                    21 (100)
   Upper leg                               20 (95.2)
   Groin                                   21 (100)
   Lower leg/ankle                         9 (42.9)
   Foot                                    14 (66.7)
   Other                                   20 (95.2)
  Wound area                                
   Small: \<10 cm^[@B2]^                   17 (81)
   Medium: \>10 and \<25 cm^[@B2]^         4 (19.1)
   Large: \>25 cm^[@B2]^                   0
   Closed surgical wound                   0
   Not applicable                          0
  Wound duration                            
   Primary                                 16 (76.2)
   Recurrent                               5 (23.8)
  Time/duration of wounds                   
   \<1 Week                                0
   1--2 Weeks                              2 (9.5)
   2--4 Weeks                              2 (9.5)
   4--6 Weeks                              3 (14.3)
   6 Weeks to \<3 months                   4 (19.1)
   3 Months to \<6 months                  3 (14.3)
   6 Months to \<1 year                    1 (4.8)
   1 Year to \<5 years                     3 (14.3)
   5 Years or more                         1 (4.8)
   Do not know                             2 (9.5)
  Wound infection                           
   Yes                                     9 (42.9)
   No                                      10 (47.6)
   Unknown                                 2 (9.5)
  Frequency of dressing change              
   Twice daily                             6 (28.6)
   Daily                                   6 (28.6)
   Alternate days                          3 (14.3)
   Two to three times per week             5 (23.8)
   Once a week                             1 (4.8)
   Other                                   0

One of the fundamental aims of the ILF is to support countries in the development of data to establish the size of the problem of chronic edema. Such data are essential in supporting the introduction of evidence-based practice and enabling each national framework to argue for appropriate financing and reimbursement.^[@B17]^ According to the aims of LIMPRINT as an international epidemiological research study; the preliminary demographic results of this study provided evidence-based data for the demographic and clinical properties of Turkish lymphedema patients. The LIMPRINT study brought a great opportunity and vision to our community. The reimbursement of pressure garments was very low in grades 2 and 3 lymphedema patients in Turkey. The ALA have prepared a file for reimbursement of care about the condition and impact of lymphedema based on the results of the LIMPRINT-Turkey study. As a partner of the ILF and of the LIMPRINT study, ALA have summarized and indicated the characteristics of Turkish lymphedema patients and demonstrated their efforts for increasing the awareness and collaboration between health professionals on a national basis. The Turkish Social Security Institution has had meetings with ALA members, made rectification, and taken the decision to pay more for the reimbursement of pressure garments for lymphedema patients with grades 2 and 3 lymphedema. We believe that the final data indicate not only the size of the problem but also the impact of chronic edema on patient lives in terms of functionality and QoL. This will assist lymphedema services to provide evidence-based care. The Turkish LIMPRINT study results demonstrate that many patients cannot access treatment services because of the distance and cannot afford to pay for costly treatments as these are not completely reimbursed. We hope this evidence-based data will change the national policies for the care of Turkish patients with lymphedema or chronic edema.

Conclusion {#s004}
==========

This final LIMPRINT data reflect that upper extremity lymphedema is more common than lower extremity and the major cause is cancer treatment, predominantly breast cancer in the Turkish LIMPRINT. The most striking results are that the patients suffer for a long time, most of the patients have uncontrolled lymphedema mostly grade 2 and have not received any previous treatment before the study. Turkish patients had less wounds compared with other studies undertaken in the LIMPRINT study. This is most certainly because of the center characteristics that were rehabilitation services treating a high proportion of cancer patients, particularly breast cancer, rather than dermatology or vascular surgery services. The majority of patients had reduced functional status and decreased QoL. Although most of the patients had social health security for free complex decongestive therapy treatment, their ability to access these centers was more difficult than previously estimated. National health policies and planning are needed for the prevention, diagnosis, and treatment of those suffering this neglected condition in Turkish patients.
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